VNQ vs XBI
Vanguard Real Estate ETF vs SPDR S&P Biotech ETF
- • VNQ has the lower expense ratio at 0.13% vs 0.35% for XBI.
- • VNQ pays a higher dividend yield (3.62%).
Side-by-side metrics
| Metric | VNQ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.13% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.62% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $69.95B | $8.30B |
YTD return | 10.90% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.07 | 1.09 |
P/E ratio | 32.43 | — |
Last price | $96.39 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VNQ top holdings
| VRTPX | Vanguard Real Estate II Index | 14.50% |
| WELL | Welltower Inc | 7.69% |
| PLD | Prologis Inc | 7.03% |
| EQIX | Equinix Inc | 5.51% |
| AMT | American Tower Corp | 4.63% |
| DLR | Digital Realty Trust Inc | 3.55% |
| SPG | Simon Property Group Inc | 3.49% |
| O | Realty Income Corp | 3.20% |
| PSA | Public Storage | 2.45% |
| CBRE | CBRE Group Inc Class A | 2.31% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VNQ
VNQ (Vanguard Real Estate ETF) is US REITs and real-estate operating companies. Managed by Vanguard, the fund carries $69.9B in assets under management, an expense ratio of 0.13%, a dividend yield of 3.62%. Its largest holding is Vanguard Real Estate II Index (VRTPX), which represents 14.5% of the portfolio. Real Estate is the fund's largest sector exposure at 99.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.